ÃĪ«¤Þ°_ªº¦åºÞ©Ê¤ô¸~

¦åºÞ©Ê¤ô¸~ (angioedema) ¥i¥HÅý§A¤@¬íÅÜÁy¡A¦åºÞ©Ê¤ô¸~¬O¤@ºØ¬ðµo©Êªº²`³¡¥Ö½§©ÎÂH½¤¤ô¸~¡C

ÅU¦W«ä¸q¡A¦åºÞ³q³z«×¤j´T¼W¥[¡AÅý²GÅé±q¦åºÞº¯³z¨ì²Õ´¤º¡A§Y³y¦¨¤ô¸~¡C

³y¦¨¦åºÞ©Ê¤ô¸~ªº­ì¦]«Ü¦h¡A¥]¬A·P¬V¡B­¹ª«¡BÃĪ«µ¥µ¥¡A³q±`±N¦åºÞ©Ê¤ô¸~®Ú¾Ú¯f¦]¾Ç¤À¦¨¡G

(1) ¥¨²Ó­M¬¡¤Æ«¬ (mast cells activation)¡G¥]¬A¹L±Ó¤ÏÀ³¡A¨Ò¦pIgE¬ÛÃöªº¹L±Ó¤ÏÀ³¡Bª½±µ¨ë¿E¥¨²Ó­M¡BNSAIDs©ÎAspirinµ¥µ¥¡C

(2) ½w°Ê¯À¥Í¦¨«¬ (generation of bradykinin)¡G³ÌµÛ¦Wªº´N¬O­°¦åÀ£ÃÄ«~ACEI¤Þ°_ªº¦åºÞ©Ê¤ô¸~¡A¥t¤@­Ó´¿¸g³Q´£¨ìªº¬O¤fªA­°¦å¿}ÃÄ«~DPP-§í¨î¾¯¡C

(3) ¾÷Âॼ©ú«¬ (unknown mechanisms)¡G¨Ò¦p·P¬V¡B¶tÂ÷¤lªýÂ_¾¯©Î¨ä¥LÃÄ«~¤Þ°_ªº¡A¬Æ¦Ü¬O¶Ý¥ì¬õ©Ê²y¹L¦h¯g­Ô¸s (Hypereosinophilic syndrome) µ¥µ¥¡C

ÈÐACEI¤Þ°_ªº¦åºÞ©Ê¤ô¸~³Ì¬°¨å«¬ÈÐ

ACEI (¦åºÞ±i¤O¯ÀÂà¤Æ–¡§í¨î¾¯)¡A¦]¬°¾÷Â઺Ãö«Y¡A§í¨î¦åºÞ±i¤O¯ÀÂà¤Æ–¡¡A·|´î¤Ö½w°Ê¯À (bradykinin) ³Q¤À¸Ñ¡A¦]¦¹¼W¥[½w°Ê¯À¡C

¦Ó½w°Ê¯À·|³y¦¨¦åºÞÂX±i¡B¼W¥[¦åºÞ³q³z«×¡A¦]¦¹¾É­P¦åºÞ¤ô¸~¡C½Ðª`·N¡A³oÃþ¾÷Âà¨Ã«DÈйL±Ó¤ÏÀ³ÈСA§ó¦h®É­Ô¤Þ°_ªº¬OÈиz­G¹DÂH½¤¤ô¸~ÈСA¾É­P¸¡µh¡Bäú¤ß¡B¹Ã¦R¡B¸¡Âm¡C

ÈЦ]¬°¸z­G¹D¯gª¬»P³oÃþÃÄ«~ªº¾÷Âण·f¹Ç¡A©Ò¥H«D±`®e©ö»~¶E©Îº|±¼¡A½Ð¯S§O¤p¤ß¡CÈÐ

½w°Ê¯À¤Þ°_ªº¦åºÞ¤ô¸~¡A¦]¬°»P²Õ´ÓiµLÃö¡A¨Ï¥Î§Ü²Õ´ÓiÃÄ«~¡BµÇ¤W¸¢¯À©ÎÃþ©T¾J¬OÈеL®ÄªºÈСC

ÁöµM¦³°w¹ï½w°Ê¯À¾÷Â઺·sÃÄ (icatibant¡Becallantide) ¥iªvÀøACEI¤Þ°_ªº¦åºÞ¤ô¸~¡A¦ý¥Ø«e¨S¿ìªk¨ú±o¡A¤]¬OªPµM¡C

°£¤F°±ÃÄ (°±¤îACEIªvÀø)¡B°µ¸Ó°µªº (ºZ³q©I§l¹D»P¨ä¥L¤ä«ù©ÊÀøªk)¡B®³¤£¨ìªº·sÃÄ¥~¡A´¿¦³¯f¨Ò³ø§i¨Ï¥ÎÈзsÂA§N­á¦å¼ß (FFP)ÈЪvÀøACEI¤Þ°_ªº¦åºÞ¤ô¸~¡A¦]¬°FFP¤¤¥]¬AACE³o­Ó»Ã¯À¡A¦b¯f¨Ò³ø§i¤¤¡A¥i§Ö³t§ïµ½¦åºÞ¤ô¸~¯gª¬¡C

°£¤FACEI¥~¡A¨ä¥L¥]¬AAspirin¡BNSAID¡B¶tÂ÷¤lªýÂ_¾¯µ¥¡A¦b¯f¨Ò³ø§i¤¤³£³Q³ø§i¥i¯à¤Þ°_¦åºÞ¤ô¸~¡C